Abstract for presentation at International Association for Child and Adolescent Psychiatry and Allied Professions Congress

An open-label trial of Reboxetine in children and adolescents with Attention-Deficit/Hyperactivity Disorder

  • Mehdi Tehrani-Doost, 1-Tehran University of Medical Sciences, deparment of psychiatry; 2-Institute for Cognitive Science Studies, Iran
  • Zahra Shahrivar, Tehran University of Medical Sciences, deparment of psychiatry, Iran
  • Shirin Moallemi, Tehran University of Medical Sciences, deparment of psychiatry, Iran

    • Objective: The main aim of this study was to assess the effectiveness and tolerability of reboxetine, a selective norepinephrine reuptake inhibitor, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
    Method: Twenty children and adolescents, aged 6 to 16 (mean: 10.29; SD=2.72) years, diagnosed with ADHD were enrolled in a 6 – week open-label trial. Assessments included ADHD Rating Scale (home version), Conners’ Parent Rating Scale-Revised (Short Version) (CPRS-R (s)). The dose of reboxetine was between 3 and 6 mg / day (mean: 4.41).
    Results: A significant decrease in ADHD symptoms, as measured by (CPRS-R (s)) was observed. This reduction was significant after two weeks of treatment (p<0.001). The oppositional symptoms were also decreased significantly (p<0.05). Reboxetine was relatively tolerated. The most common adverse effects were decreased appetite, constipation, sleep problem, and dry mouth.
    Conclusion: This open-label study suggests the effectiveness of reboxetine in the treatment of ADHD in children and adolescents. Controlled studies in larger samples are needed to test the efficacy of reboxetine in ADHD.
    Keywords: reboxetine, attention-deficit/hyperactivity disorder (ADHD)

    Conference Organiser - ICMS Pty Ltd